Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Oncology-focused pharma companies

Pharmaceutical intelligence for Oncology-focused pharma companies with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Assets
1

Recent signals(2)

ClinicalJuly 29, 2026

NCI initiates trial for preoperative radiation therapy in recurrent abdominal adrenocortical carcinoma

The National Cancer Institute is testing a new external beam radiation therapy before surgery in patients with resectable recurrent adrenocortical carcinoma.

ClinicalJune 28, 2026

Review Highlights Inflammation's Role in Cancer and Small-Molecule Therapeutics Development

The review discusses the critical role of inflammation in cancer and recent advancements in small-molecule therapeutics targeting inflammatory pathways.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(2)

ClinicalJuly 29, 2026

NCI initiates trial for preoperative radiation therapy in recurrent abdominal adrenocortical carcinoma

The National Cancer Institute is testing a new external beam radiation therapy before surgery in patients with resectable recurrent adrenocortical carcinoma.

ClinicalJune 28, 2026

Review Highlights Inflammation's Role in Cancer and Small-Molecule Therapeutics Development

The review discusses the critical role of inflammation in cancer and recent advancements in small-molecule therapeutics targeting inflammatory pathways.

Competitive activity

No signals indexed for this entity yet.

Assets

NCI →

Therapeutic areas

Adrenocortical Carcinoma →
Oncology →

Indications

Adrenocortical Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.